Gene Therapy and Immune Senescence View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2009-01-01

AUTHORS

Jian Chen , Hui-Chen Hsu , John D. Mountz

ABSTRACT

Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a “suicide” gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome. More... »

PAGES

1629-1646

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76

DOI

http://dx.doi.org/10.1007/978-1-4020-9063-9_76

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007480986


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Jian", 
        "id": "sg:person.01144563407.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hsu", 
        "givenName": "Hui-Chen", 
        "id": "sg:person.01263522210.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263522210.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mountz", 
        "givenName": "John D.", 
        "id": "sg:person.07550405624.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-01-01", 
    "datePublishedReg": "2009-01-01", 
    "description": "Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a \u201csuicide\u201d gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome.", 
    "editor": [
      {
        "familyName": "Fulop", 
        "givenName": "Tamas", 
        "type": "Person"
      }, 
      {
        "familyName": "Franceschi", 
        "givenName": "Claudio", 
        "type": "Person"
      }, 
      {
        "familyName": "Hirokawa", 
        "givenName": "Katsuiku", 
        "type": "Person"
      }, 
      {
        "familyName": "Pawelec", 
        "givenName": "Graham", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4020-9063-9_76", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4020-9062-2", 
        "978-1-4020-9063-9"
      ], 
      "name": "Handbook on Immunosenescence", 
      "type": "Book"
    }, 
    "keywords": [
      "gene therapy", 
      "thymidine kinase", 
      "large capacity", 
      "potential integration", 
      "gene integration", 
      "adverse position", 
      "certain vector", 
      "third consideration", 
      "transgene", 
      "vector", 
      "duration of therapy", 
      "integration", 
      "second consideration", 
      "therapy duration", 
      "immune senescence", 
      "delivery", 
      "immune response", 
      "therapy", 
      "adverse effects", 
      "capacity", 
      "immunogenicity", 
      "advances", 
      "consideration", 
      "duration", 
      "safety", 
      "reciprocal relationship", 
      "suicide", 
      "genes", 
      "Table 1", 
      "cells", 
      "results", 
      "response", 
      "factors", 
      "kinase", 
      "senescence", 
      "effect", 
      "relationship", 
      "position", 
      "genome", 
      "therapy immunogenicity"
    ], 
    "name": "Gene Therapy and Immune Senescence", 
    "pagination": "1629-1646", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007480986"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4020-9063-9_76"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4020-9063-9_76", 
      "https://app.dimensions.ai/details/publication/pub.1007480986"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T20:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_214.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4020-9063-9_76"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4020-9063-9_76'


 

This table displays all metadata directly associated to this object as RDF triples.

129 TRIPLES      23 PREDICATES      65 URIs      58 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4020-9063-9_76 schema:about anzsrc-for:10
2 anzsrc-for:1004
3 schema:author N552a164e11054dbab47072445c45913d
4 schema:datePublished 2009-01-01
5 schema:datePublishedReg 2009-01-01
6 schema:description Gene therapy can be classified according to the vector used for gene therapy and the transgene that will be expressed as a result of the gene therapy. One consideration for gene therapy is that certain vectors have larger capacities than others to incorporate genes. The second consideration is the duration of therapy, which depends upon the immune response after delivery of the therapy. Therapy duration usually exhibits a reciprocal relationship to therapy immunogenicity. A third consideration is safety. This is related both to the immunogenicity and adverse effects of potential integration. These factors are shown in Table 1. Advances to enable gene integration with safety have been carried out using a “suicide” gene, such as thymidine kinase (TK) that can be upregulated to eliminate cells in which the transgene has integrated into an adverse position in the genome.
7 schema:editor N0bdc1e38bc094316a7fd06d6764988b3
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N09f3bcb0ea834d9da1f5b575b27d018c
12 schema:keywords Table 1
13 advances
14 adverse effects
15 adverse position
16 capacity
17 cells
18 certain vector
19 consideration
20 delivery
21 duration
22 duration of therapy
23 effect
24 factors
25 gene integration
26 gene therapy
27 genes
28 genome
29 immune response
30 immune senescence
31 immunogenicity
32 integration
33 kinase
34 large capacity
35 position
36 potential integration
37 reciprocal relationship
38 relationship
39 response
40 results
41 safety
42 second consideration
43 senescence
44 suicide
45 therapy
46 therapy duration
47 therapy immunogenicity
48 third consideration
49 thymidine kinase
50 transgene
51 vector
52 schema:name Gene Therapy and Immune Senescence
53 schema:pagination 1629-1646
54 schema:productId Nd441c0a5e3c9477384dc8fb59f82f0cf
55 Nf3d8380628c64bb4855fd82770981daf
56 schema:publisher N71211cbb692d449092fcb440798b0ad8
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007480986
58 https://doi.org/10.1007/978-1-4020-9063-9_76
59 schema:sdDatePublished 2021-12-01T20:00
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Nabf6794a0c0d4352a2f026d2a2438e57
62 schema:url https://doi.org/10.1007/978-1-4020-9063-9_76
63 sgo:license sg:explorer/license/
64 sgo:sdDataset chapters
65 rdf:type schema:Chapter
66 N09f3bcb0ea834d9da1f5b575b27d018c schema:isbn 978-1-4020-9062-2
67 978-1-4020-9063-9
68 schema:name Handbook on Immunosenescence
69 rdf:type schema:Book
70 N0bdc1e38bc094316a7fd06d6764988b3 rdf:first N48c3a298c3b947a4a6e435b5307041e6
71 rdf:rest Nd8d4777329db42bb9a2a6fca02ea854a
72 N31410d349daa432db66c3825831d1208 rdf:first sg:person.01263522210.53
73 rdf:rest N6da5531a14004ec28b3f7f5acf6dae11
74 N48c3a298c3b947a4a6e435b5307041e6 schema:familyName Fulop
75 schema:givenName Tamas
76 rdf:type schema:Person
77 N552a164e11054dbab47072445c45913d rdf:first sg:person.01144563407.49
78 rdf:rest N31410d349daa432db66c3825831d1208
79 N55b59f11bd7845a2ae938bd3656adc66 schema:familyName Pawelec
80 schema:givenName Graham
81 rdf:type schema:Person
82 N65c85cea77e74512aa7c2b3e75f0c0a8 schema:familyName Franceschi
83 schema:givenName Claudio
84 rdf:type schema:Person
85 N6da5531a14004ec28b3f7f5acf6dae11 rdf:first sg:person.07550405624.18
86 rdf:rest rdf:nil
87 N71211cbb692d449092fcb440798b0ad8 schema:name Springer Nature
88 rdf:type schema:Organisation
89 N8f347226dbb94452b554a5230ed08694 rdf:first Nb0eb125758bd4809ba4abef88ff8e3c1
90 rdf:rest N9ab489df005e47b994ad8916a1231515
91 N9ab489df005e47b994ad8916a1231515 rdf:first N55b59f11bd7845a2ae938bd3656adc66
92 rdf:rest rdf:nil
93 Nabf6794a0c0d4352a2f026d2a2438e57 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 Nb0eb125758bd4809ba4abef88ff8e3c1 schema:familyName Hirokawa
96 schema:givenName Katsuiku
97 rdf:type schema:Person
98 Nd441c0a5e3c9477384dc8fb59f82f0cf schema:name dimensions_id
99 schema:value pub.1007480986
100 rdf:type schema:PropertyValue
101 Nd8d4777329db42bb9a2a6fca02ea854a rdf:first N65c85cea77e74512aa7c2b3e75f0c0a8
102 rdf:rest N8f347226dbb94452b554a5230ed08694
103 Nf3d8380628c64bb4855fd82770981daf schema:name doi
104 schema:value 10.1007/978-1-4020-9063-9_76
105 rdf:type schema:PropertyValue
106 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
107 schema:name Technology
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
110 schema:name Medical Biotechnology
111 rdf:type schema:DefinedTerm
112 sg:person.01144563407.49 schema:affiliation grid-institutes:grid.265892.2
113 schema:familyName Chen
114 schema:givenName Jian
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49
116 rdf:type schema:Person
117 sg:person.01263522210.53 schema:affiliation grid-institutes:grid.265892.2
118 schema:familyName Hsu
119 schema:givenName Hui-Chen
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263522210.53
121 rdf:type schema:Person
122 sg:person.07550405624.18 schema:affiliation grid-institutes:grid.265892.2
123 schema:familyName Mountz
124 schema:givenName John D.
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18
126 rdf:type schema:Person
127 grid-institutes:grid.265892.2 schema:alternateName Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA
128 schema:name Birmingham VA Medical Center, 1825 University Blvd SHEL no B310, The University of Alabama at Birmingham, 35294, Birmingham, Alabama, USA
129 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...